Genetic Testing Reveals Hidden Gaps in Care for Women at High Breast Cancer Risk

A ground-breaking new study has pulled back the curtain on a troubling paradox in modern cancer medicine: even when women learn they carry inherited genetic mutations that dramatically raise their lifetime risk of breast cancer, the support systems designed to help them manage that risk often fail to reach the people who need them most. The research, led by a team at Stanford University School of Medicine in collaboration with the patient advocacy organization Facing Our Risk of Cancer Empowered (FORCE), was published in the journal Breast Cancer Research and Treatment and offers one of the most detailed portraits to date of what happens after a positive genetic test result.

The scientific context is critical. Germline genetic testing, which examines DNA inherited from parents for pathogenic variants in genes such as BRCA1, BRCA2, CHEK2, PALB2, ATM and TP53, has expanded rapidly in recent years. Guidelines from bodies including the National Comprehensive Cancer Network and the American Society of Clinical Oncology now recommend testing for ever-broader groups of patients and family members. Carrying a pathogenic variant in one of the twelve genes studied, which included ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, RAD51C, RAD51D, STK11 and TP53, confers an elevated lifetime risk of breast cancer and triggers a distinct clinical pathway: intensified screening with mammography and magnetic resonance imaging, consideration of preventive medications, and, for some women, risk-reducing mastectomy.

Yet while the barriers to getting tested in the first place have been well studied, far less has been known about what women experience once they receive their results. Do they find the screening services they need? Can they afford the surveillance or the surgery? Who helps them emotionally and financially through decisions that can reshape their lives? To answer these questions, the research team designed a 38-question online survey, developed by FORCE and administered electronically to the organization’s subscribers between February and May 2024.

The numbers tell a striking story. Of the 1,025 respondents who began the survey, 937 were women meeting the eligibility criteria of female sex and a germline pathogenic variant conferring elevated breast cancer risk. The cohort was overwhelmingly non-Hispanic White, at 91.7 percent, and predominantly American, with 81.6 percent from the United States. The most common variants were BRCA2, carried by 31.4 percent of respondents, followed by BRCA1 at 25.5 percent and CHEK2 at 9.2 percent. That concentration matters because BRCA1 and BRCA2 carriers face some of the highest lifetime risks and have the most intensive management options available to them.

On the surface, the respondents appeared well connected to information. The most frequently used resources were education and information services about medical options, used by 39.3 percent, and peer support programs, used by 28.1 percent. These findings suggest that advocacy organizations and peer networks play a central role in helping genetically high-risk women navigate a bewildering array of choices. But the picture darkened sharply when the researchers turned to financial support services.

Only 4.0 percent of respondents reported using financial navigation, and just 5.3 percent used financial support services, yet up to 45 percent reported needing such assistance. That gap, between a small fraction receiving help and nearly half needing it, may be the study’s most consequential finding. It points to a systemic blind spot: the medical system has become skilled at identifying genetic risk but has not built the financial infrastructure to help patients act on what they learn.

Screening itself, the cornerstone of risk management for women who defer or avoid surgery, carried hidden burdens. Among survey respondents, 53.8 percent used mammography, 42.2 percent used magnetic resonance imaging and 19.4 percent used ultrasound. Within this screening population, 37.8 percent found it hard to prepare emotionally for their results, an experience that clinicians recognize as a recurring cycle of anxiety, since high-risk women face imaging multiple times a year for decades. Meanwhile, 14 percent found it hard to pay for screening, a reminder that even diagnostic imaging can strain household budgets when it is required far more frequently than for average-risk women.

The decision to undergo risk-reducing mastectomy proved equally fraught. Just over one-third of respondents, 37.1 percent, found it hard to decide whether to have the operation at all, a choice that involves weighing the magnitude of cancer risk reduction against the permanence of surgery. Once the decision was made, the difficulties multiplied: 64.0 percent found physical recovery hard, 60.2 percent found emotional recovery hard, and 24.7 percent found paying for the surgery hard. These figures align with a growing body of surgical literature examining survival outcomes and quality of life after bilateral risk-reducing mastectomy in BRCA carriers, and they underscore that the operation is not simply a checkbox on a prevention pathway but a major life event with prolonged physical and psychological consequences.

What makes this study methodologically distinctive is its origin within the patient community itself. By developing the survey through FORCE, the researchers captured questions and concerns that might never appear in investigator-initiated instruments, and the partnership between a Stanford academic team and an advocacy organization represents a model of patient-centered research. At the same time, the authors and readers alike must weigh the limitations: the sample skews heavily toward non-Hispanic White, English-speaking women connected to an advocacy organization, a group likely to be more informed and more resourced than the average carrier of a pathogenic variant. If even this relatively advantaged population reports unmet financial needs in such high proportions, the true scale of the problem in the broader, more diverse population of mutation carriers is likely greater still.

The study’s conclusion is unambiguous: in this contemporary sample of women at elevated risk of breast cancer, more than one-third had unmet financial needs and up to two-thirds had difficulty with screening or risk-reducing surgery. Closing these gaps, the authors argue, will be essential to improving outcomes for women with hereditary breast cancer risk. As genetic testing becomes cheaper, faster and more widespread, the number of women entering this high-risk pathway will only grow. The research suggests that the next frontier of precision oncology is not genomic at all. It is the construction of support systems, financial navigation, affordable screening, and emotional recovery care, robust enough to match the power of the DNA sequence that starts the journey.

Subject of Research: Unmet needs and utilization of screening, prevention and financial support resources among women carrying breast cancer susceptibility gene variants

Article Title: Awareness, need and utilization of breast cancer risk management resources in women with hereditary cancer susceptibility

Article References: Parkinson, G., Friedman, S., Hodan, R., & Kurian, A. W. (2026). Awareness, need and utilization of breast cancer risk management resources in women with hereditary cancer susceptibility. Breast Cancer Research and Treatment, 220(1), Article 5. https://doi.org/10.1007/s10549-026-08104-2

Image Credits: AI Generated

DOI: 10.1007/s10549-026-08104-2

Keywords: breast cancer, genetic testing, BRCA1, BRCA2, CHEK2, hereditary cancer, risk-reducing mastectomy, cancer screening, financial navigation, patient advocacy, FORCE, genetic counseling